
    
      This study had two parts:

        -  Part 1, collecting long-term safety, tolerability, efficacy and health outcomes data
           through approximately 30-Jun-2016 until all end of study (EOS) visits of Part 1 and last
           follow-up visit through Jan-2017 and

        -  Part 2, collecting limited safety and tolerability data until approximately 30 Jun 2018,
           in a subset of patients who participated in Part 1, and other eligible patients from
           ongoing fingolimod trials.
    
  